VC
Methodology breakdown computing — it will appear here on its own.
Vericel Corp (VCEL) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-06). See the full ratio breakdown and business-activity screen below for the reasoning.
Computing the full ratio and business-activity breakdown for VCEL — this runs off the critical path so the page paints first. It will appear here on its own.
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Ken Fisher | Fisher Asset Management | $8M | 0.0% | 2026-06-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 31.20 | NEUTRAL |
| Stochastic %K (14) | 16.53 | BUY |
| CCI (20) | -128.66 | BUY |
| Williams %R (14) | -83.47 | BUY |
| MACD (12,26,9) | -0.31 | SELL |
| ROC (10) | -6.90 | SELL |
| Momentum (10) | -2.84 | SELL |
| EMA (10) | 39.70 | SELL |
| SMA (10) | 39.72 | SELL |
| EMA (20) | 40.99 | SELL |
| SMA (20) | 41.34 | SELL |
| EMA (30) | 41.73 | SELL |
| SMA (30) | 42.60 | SELL |
| EMA (50) | 42.02 | SELL |
| SMA (50) | 44.17 | SELL |
| EMA (100) | 40.86 | SELL |
| SMA (100) | 40.40 | SELL |
| EMA (200) | 38.99 | SELL |
| SMA (200) | 38.15 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.
Background via Yahoo Finance — informational, not part of the verdict.
🔴 AVOID
The main driver: lagging the market by 13.8%. Too many signals pointing the wrong way. Wait for the picture to improve before committing capital.
Scores: 1 bullish / 3 bearish
Weak — low conviction, small size or skip
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 62 |
| ⏰ 4H | BEARISH | 36 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | BULLISH | 130 |
| ⏲ 5-Min | BULLISH | 234 |
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-08 · Asset managers net 912361 (-21819)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.